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Abstract Bacteria of the genus Staphylococcus are com-
mon pathogens responsible for a broad spectrum of human
and animal infections and belong to the most important
etiological factors causing food poisoning. Because of rapid
increase in the prevalence of isolation of staphylococci
resistant to many antibiotics, there is an urgent need for
the development of new alternative chemotherapeutics. A
number of studies have recently demonstrated the strong
potential of peptidoglycan hydrolases (PHs) to control and
treat infections caused by this group of bacteria. PHs
cause rapid lysis and death of bacterial cells. The review
concentrates on enzymes hydrolyzing peptidoglycan of
staphylococci. Usually, they are characterized by high
specificity to only Staphylococcus aureus cell wall com-
ponents; however, some of them are also able to lyse cells
of other staphylococci, e.g., Staphylococcus epidermidis-
human pathogen of growing importance and also other
groups of bacteria. Some PHs strengthen the bactericidal
or bacteriostatic activity of common antibiotics, and as a
result, they should be considered as component of com-
bined therapy which could definitely reduced the devel-
opment of bacterial resistance to both enzymes and
antibiotics. The preliminary research revealed that most
of these enzymes can be produced using heterologous,
especially Escherichia coli expression systems; however,
still much effort is required to develop more efficient and
large-scale production technologies. This review discusses
current state on knowledge with emphasis on the possi-
bilities of application of PHs in the context of therapeutics
for infections caused by staphylococci.
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Introduction
Bacteria of the Staphylococcus genus belong to the most im-
portant human and animal pathogens. They are responsible for
a broad spectrum of diseases: skin and ocular infections, food
poisoning, pneumonia, meningitis, endocarditis, and osteomy-
elitis. Its high pathogenicity is based on production of a wide
array of virulence factors such as protein A, coagulase, colla-
genase, hyaluronidase, hemolysins, lipases, different toxins,
adhesive proteins, and also proteins affecting the biofilm for-
mation. Additionally, Staphylococcus aureus has developed
several mechanisms that enable the pathogen’s escape from
protective immune responses of infected human or animal
organisms. Among them, protein A (SpA), staphylokinase,
and staphylococcal binder of immunoglobulin are the most
important and the best characterized (Kim et al. 2011). The
detailed mechanisms of evasion of immune defense by S.
aureus are presented in several excellent review articles
(Lambris et al. 2008; Laarman et al. 2010; Langley et al. 2010).
S. aureus infections are especially difficult to treat be-
cause of the evolved resistance to antimicrobial drugs. As
rapidly as new antibiotics are introduced, staphylococci
have developed efficient mechanisms to neutralize them.
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In 1928, the Scottish microbiologist Fleming discovered
penicillin which was introduced into clinical practice in
the early 1940s. However, in 1942, penicillin-resistant
staphylococci were recognized, first in hospitals and subse-
quently in the community, and by the late 1960s, more than
80 % of both community- and hospital-acquired staphylo-
coccal isolates were resistant to penicillin (Lowy 2003;
Klein et al. 2007). To overcome infections caused by
β-lactamase-producing S. aureus, a team of scientists from
the UK-based pharmaceutical company Beecham produced in
1959 a new, semisynthetic, narrow spectrum, penicillinase-
resistant antibiotic called methicillin. However, in 1960,
Jevons and coworkers analyzing the group of 5,440 S. aureus
isolates from one hospital-Colindale (London, UK)-found
three strains resistant to methicillin (Jevons et al. 1963).
Soon after that isolation, S. aureus strains resistant to this
antibiotic have been reported in other countries including
Turkey (Cetin and Ang 1962), India (Pal and Ghosh Ray
1964), and Poland (Borowski et al. 1964), where methicillin
or other penicillinase-resistant penicillins were not yet avail-
able (Ayliffe 1997). Methicillin resistance is associated with
the acquisition of a particular resistance island-staphylococcal
cassette chromosome mec (SCCmec). The most important ele-
ment of SCCmec is a genemecA coding forβ-lactam-insensitive
enzyme of cell wall synthesis called penicillin binding protein 2a
or 2′ (PBP 2a or PBP 2′), a 78-kDa protein with low affinity for
β-lactam antibiotics. The methicillin-resistant S. aureus
(MRSA) strains are very often classified as multidrug resistant
(MDR), which is a consequence of incorporation of many other
determinants of resistance into the sequence of SCCmec, which
acts as a hotspot of integration for genetic mobile elements such
as plasmids, transposons, and insertion sequences (Lowy 2003;
Stefani and Goglio 2010).
Initially, MRSA strains were encountered only in hospi-
tals and are called Healthcare Associated MRSA (HA-
MRSA). In the early 1990s, the “new group” of MRSA
called community-acquired (CA-MRSA) was identified in
indigenous populations in Western Australia. By the PFGE
analysis, it was shown that these strains were unrelated to
hospital clones of MRSA isolated previously in Australia. In
contrast to typical HA-MRSA, they were susceptible to most
antibiotics other than β-lactams but exhibited an unexpected
virulence potential (Udo et al. 1993). In the USA, the first
well-documented cases of MRSA infection that were truly
community-associated occurred in otherwise healthy chil-
dren in 1997. These children had no risk factors for devel-
oping MRSA and all died of severe infection, suggesting
that these CA-MRSA strains were especially virulent. Like
their Australian counterparts, these CA-MRSA isolates were
unrelated to hospital-associated clones and were susceptible
to most antibiotics (CDC 1999; Chambers and DeLeo
2009). The staphylococci of both HA and CA-MRSA groups
have spread rapidly all over the world and are a serious
clinical problem. Recent figures show that infections due to
MRSA are responsible for 50 % of hospital-acquired infec-
tions with increasing morbidity and mortality, and in some
areas, more than 50 % of S. aureus bacteremias are caused
by MRSA (Taiwo 2009). The level of importance of infec-
tions caused by staphylococci has been presented by Klein
et al. (2007). According to these authors, a number of S.
aureus-related hospitalizations in the USA in the period of
time from 1999 to 2005 increased by 62 %, from 294,570 to
477,927, and the estimated number of MRSA-related hos-
pitalizations increased more than two times from 127,036 to
278,203. The authors also noticed that in 2005 there were
about 11,400 deaths as a result of S. aureus infection, of
which about 6,640 were MRSA-related (Klein et al. 2007).
As it was mentioned above, MRSA strains often represent
the MDR phenotype, but the most worrisome problem is the
appearance of strains exhibiting resistance or reduced sus-
ceptibility to glycopeptides, considered as a gold standard
for MRSA therapy. Three classes of vancomycin-resistant S.
aureus that differ in vancomycin susceptibilities have
emerged: vancomycin-intermediate S. aureus (VISA), het-
erogenous vancomycin-intermediate S. aureus (hVISA),
and high-level vancomycin-resistant S. aureus (VRSA)
(Howden et al. 2010). However, so far, only several strains
exhibiting fully vancomycin-resistant strains of S. aureus
(VRSA) due to the acquisition of the vanA gene from
vancomycin-resistant enterococci have been reported in the
USA (Perichon and Courvalin 2009), Iran (Aligholi et al.
2008), and India (Saha et al. 2008). The isolation of VISA
and hVISA seems to be a serious emerging problem. In
contrast to VRSA, the strains with reduced susceptibility
to glycopeptides exhibit high spreading potential. After the
first reports of VISA and hVISA from Japan (Hiramatsu et
al. 1997), it did not take long for this resistance phenotype to
be recognized around the world (Howden et al. 2010).
The problem of staphylococci-related infections is addi-
tionally enhanced by the staphylococcal ability of biofilm
formation. Biofilm is a structured community of bacterial
cells enclosed in a self-produced polymeric matrix and adher-
ent to an inert or living surface (Costerton et al. 1999).
Microorganisms in biofilms are evidently less susceptible to
antibiotics, importantly due to altered growth rate and delayed
penetration of antimicrobial agents within the biofilm struc-
ture (Melchior et al. 2006, 2007). Some of the previous studies
proved that the biofilm-forming bacteria may be in fact 10–
1,000 times more resistant to antimicrobial agents than the
same cells growing in a planktonic manner as it takes place
during the in vitro assays of antibiotic activity (Amorena et al.
1999; Melchior et al. 2006, 2007). Antibiotic resistance of
biofilms often leads to the failure of conventional antibiotic
therapy and recurrence of infections.
S. aureus and other bacteria of this genus, including
MRSA, are also important animal pathogens. The number
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of publications presenting isolation of strains resistant to
methicillin from animal sources has increased evidentially
in the last few years (Weese and van Duijkeren 2010;
Loeffler and Lloyd 2010). Staphylococci are also an impor-
tant problem for food technologists especially in the meat,
dairy, and fish industries (Vanderhaeghen et al. 2010).
The evident increase in the antibiotic resistance of staphylo-
cocci, one of the most common and dangerous bacterial patho-
gens, observed worldwide, stimulates the development of new
alternative, effective, and inexpensive agents for the treatment
of this group of microorganism. Some of the alternative thera-
pies in S. aureus diseases, such as bacteriophages, antimicrobial
peptides, plant- (e.g., stilbenoids and flavonoids) and animal-
derived (e.g., chitosan and propolis) compounds, vaccines, and
photodynamic therapy have been recently discussed by
Kurlenda and Grinholc (2012). The present paper is devoted
to discuss the possibilities of the prevention and treatment of
staphylococcal infections by using peptidoglycan hydrolases
(PHs), enzymes exhibiting the ability to hydrolyze bacterial cell
wall components. In our opinion, these enzymes constitute one
of the most promising but still underestimated groups of po-
tential antistaphylococcal chemotherapeutics.
Cell wall structure of S. aureus
S. aureus is a Gram-positive spherical bacterium approxi-
mately 1 μm in diameter. Its cells are surrounded by a
murein sacculus. As in the case of other Gram-positive
bacteria, the cell wall of staphylococci is composed of
teichoic acids, surface proteins, and first of all, the macro-
molecular net of peptidoglycan. The peptidoglycan is com-
posed of glycan chains made up of the alternating amino
sugars N-acetylglucosamine and N-acetylmuramic acid.
Stem pentapeptides (L-Ala-D-iso-Gln-L-Lys-D-Ala-D-Ala)
are attached to the carboxyl group of each N-acetylmuramic
acid, and interpeptide bridges (pentaglycines, made up of
glycine residues) connect the lysine component of one stem
peptide to the penultimate D-alanine of a neighboring stem
peptide in which glycan strands are cross-linked with short
peptide motives (Tomasz 2006) (Fig. 1). A major function
of the cell wall is to act as a pressure vessel, preventing
overexpansion when water enters the cell. The inhibition of
activity of enzymes, which participate in the synthesis of
peptidoglycan, is the basis of activity of many antibacterial
antibiotics such as β-lactams (e.g., penicillins and cephalo-
sporins), glycopeptides (e.g., vancomycin and teicoplanin),
fosfomycin, daptomycin, nisin, bacitracin, and many others.
The cells of bacteria, especially the Gram-positive bacteria,
which are not protected with a properly synthesized cell
wall, are not able to survive. The structure of peptidoglycan
consists of at least five types of bonds, which are molecular
targets for existing in nature bacterial cell wall hydrolyzing
enzymes, PHs. The localization of these bonds and their
corresponding enzymes is presented in Fig. 1. The targets
marked with numbers 1–4 are present in the peptidoglycan
of most genus of bacteria, while the pentaglycine interpep-
tide cross-bridge is a unique component of S. aureus cell
wall and is a specific substrate for lysostaphin, the best
known staphylococcal peptidoglycan hydrolase, but also
for many other, less known enzymes, which are character-
ized in this review. The hydrolysis of peptidoglycan by PHs
results in a strong bactericidal effect which makes this group
of enzymes an alternative antibacterial weapon, which cur-
rently is not widely used not only in clinical practice, but
also in veterinary and food technology.
In order to protect against activity of cell wall hydrolases,
bacteria have specific modifications of the backbone peptido-
glycan. Specific modifications like N-deacetylation, N-
glycolylation, O-acetylation, or modifications of amino acid
sequence of peptide bridges render some bacteria resistant to
PHs. This phenomenon should be taken into account in the
development of clinical, veterinary, or food application of this
group of enzymes (Callewaert et al. 2011).
Peptidoglycan hydrolases with antistaphylococcal
activity
Enzymes of peptidoglycan hydrolase activity are produced
by all groups of living organisms and also viruses. In the
structure of all of them, two domains can be distinguished:
catalytic N-terminal domain and C-terminal cell wall bind-
ing domain (Fig. 2). In the case of human, animal, and plant
organisms, these enzymes play an important role in the
suppression of bacterial infections as a component of innate
immune system. The bacteriophage PHs are called lysins or
endolysins, and they perform crucial roles in the viral infec-
tion cycle of the bacterial host. Interestingly, the enzymes
which are capable of hydrolyzing the peptidoglycan of the
bacterial cell envelope are ubiquitous also among bacteria
and are called autolysins. The bacterial cell wall is a dy-
namic structure, which is modified strictly according to the
“cell cycle.” The autolysins play an important role in cell
wall growth, cell separation, cell wall turnover, competence
for genetic transformation, flagellum formation, sporulation,
and in the lysis of bacteria induced by the β-lactam anti-
biotics (Shockman and Holtje 1994; Antignac et al. 2007).
Below, we have presented the most promising PHs of dif-
ferent origin, which potentially could be used as antistaphy-
lococcal agents.
Lysozymes
In this paper, the presence of lysozymes can be surprising.
In contrast to most Gram-positive bacteria, the pathogenic
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staphylococci exhibit extremely high resistance to lysozymes
of different origin, including the most popular hen egg white
lysozyme. It is crucial for their interactions with the host
organisms that produce lysozyme as an initial defense against
bacterial infection. The lack of susceptibility of the staphylo-
coccal cell wall to lysozyme has a complex background and is
still not well understood. Several studies have suggested that it
is primarily caused by O-acetylation at position C-6 of the N-
acetylmuramic acid (NAM) residue (Clarke and Dupont 1991;
Bera et al. 2005). The studies of Bera et al. (2006) revealed that
the presence of the enzyme peptidoglycan O-acetyltransferase
(OatA) in various staphylococcal species correlates with lyso-
zyme resistance and pathogenicity. The muramic acid was O-
acetylated only in pathogenic, lysozyme-resistant staphylococci
(e.g., S. aureus, S. epidermidis, Staphylococcus lugdunensis,
and others). All nonpathogenic species were lysozyme sensi-
tive (e.g., Staphylococcus carnosus, Staphylococcus
gallinarum, and Staphylococcus xylosus) or hypersensitive
(e.g., Staphylococcus equorum, Staphylococcus lentus, and
Staphylococcus arlettae) (Bera et al. 2006). It has been also
documented that the resistance of staphylococci to lysozymes
occurs due to two other important mechanisms. First, it is
caused by binding of wall teichoic acids to the C-6 position
of NAM (Bera et al. 2007). Second, it is based on extensive
cross-linking of their peptidoglycan, which results from the
regulated action of penicillin binding protein 4 (Atilano et al.
2010).
Lysozymes have been included in this review because until
now the hen egg white lysozyme is one of the few natural
antimicrobials at all and the only PH that is approved as a food
preservative in EU and several other countries. It has been also
successfully applied as a component of “active” food packing
materials (Callewaert et al. 2011). However, it does not exhibit
activity against staphylococci. Lysozyme is incontestably the
most extensively studied PH and can be a good model for
future studies of medical and food application of enzymes
hydrolyzing staphylococcal cell wall.
Lysostaphin
Lysostaphin is a zinc metalloproteinase isolated from
Staphylococcus simulans biovar staphylolyticus (Schindler
and Schuhardt 1964, 1965; Sloan et al. 1982). It degrades
the cell wall of almost all known staphylococcal species. The
target of the lysostaphin activity is the pentaglycine interpep-
tide bridges of the unique staphylococcal peptidoglycan
(Schleifer and Kandler 1972; Iversen and Grov 1973). Other
Gram-positive and Gram-negative bacteria are not susceptible

















Fig. 1 The structure of S. aureus peptidoglycan (according to Fenton et al.
2010a, with some modifications), the arrows indicate the cleavage sites: 1
N-acetyl muramidase, 2 N-acetyl-β-D-glucosaminidase, 3 N-
acetylmuramoyl-L-alanine amidase, 4 L-alanoyl-D-glutamate endopepti-
dases, and 5 interpeptide bridge endopeptidases (e.g., lysostaphin). Abbre-
viations: GlcNAc N-acetylglucosamine, MurNAc N-acetylmuramic acid






Fig. 2 Basic structure of peptidoglycan hydrolases according to
Fischetti (2008). N-terminal catalytic domain retains the activity to
cleave one of the bonds in the staphylococcal peptidoglycan, some of
the enzymes contain two catalytic domains (e.g., AtlE, LysK). Se-
quence comparison of enzymes in the same enzyme class indicates
that the catalytic region is highly conserved, while C-terminal binding
domain is highly conserved among most of S. aureus bactericidal
peptidoglycan hydrolases also belonging to different enzyme classes
and produced in different hosts (staphylococci, other bacteria, and
bacteriophages). L-short linker between functional domains
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lysostaphin is organized as a preproprotein containing a signal
peptide of 33 amino acid residues, a propeptide of 211 amino
acid residues (from which 195 are organized in 15 tandem
repeats of 13 amino acids in length), and a mature protein of
246 amino acid residues (Heinrich et al. 1987; Thumm and
Gotz 1997). The N-terminal prepeptide (signal peptide)
cleaved intracellularly and the propeptide removed extracel-
lularly by a cysteine protease do not participate in the degra-
dation of staphylococcal cells (Zhou et al. 1989). The catalytic
activity for the mature 27-kDa lysostaphin showed approxi-
mately 4.5-fold higher activity than the precursor protein, and
in fact, only this fragment of the enzyme is considered for
future applications (Thumm and Gotz 1997). The native pro-
ducer of the enzyme, S. simulans, is not susceptible to autol-
ysis because of the expression of the Lif protein (lysostaphin
immunity factor), which incorporates the serine residues into
the interpeptide bridges at positions 3 and 5 (DeHart et al.
1995; Thumm and Gotz 1997; Ehlert et al. 2000).
Incorporation of amino acids other than glycine (predominant-
ly serine and alanine) accounts for the decreased susceptibility
of many coagulase-negative staphylococci to lysostaphin,
which is unable to hydrolyse Gly-Ser, Ser-Gly, Ala-Gly, and
Gly-Ala peptide bonds (Robinson et al. 1979; Kiri et al. 2002).
The enzyme has maximum activity at pH 7.5 and about 40 °C
(Schindler and Schuhardt 1965) and is inhibited by exoge-
nously added zinc and agents that would chelate endogenous
zinc atoms such as o-phenanthroline or EDTA (Zygmunt and
Tawormina 1972; Park et al. 1995). The unique biological
activity of lysostaphin presents numerous possibilities for
applications of this enzyme as an antistaphylococcal agent in
medicine, veterinary, food industry, and also in research fields.
The presence of pentaglycine interpeptide cross-bridge and
its susceptibility to lysostaphin is a characteristic feature of S.
aureus, which is used for specific identification of this genus
of bacteria and its differentiation from the closely related
Micrococci. Because of the previously mentioned unique
organization of peptidoglycan, staphylococci are resistant to
most conventional lysis methods that use lysozyme, deter-
gents, and ultrasound. Lysostaphin is frequently used as a
staphylolytic agent for the liberation of intracellular enzymes,
nucleic acids, and cell membrane and surface components.
The enzyme was first described in 1964 (Schindler and
Schuhardt 1964), and since its discovery, it was intensively
tested as a potential chemotherapeutic agent against staphy-
lococcal infections. In the early 1970s, lysostaphin was first
successfully used for the treatment of a staphylococcal ab-
scess in a human neutropenic patient (Stark et al. 1974). The
application of the enzyme was also shown to be effective in
reducing the nasal carriage of S. aureus in humans (Harris et
al. 1967; Quickel et al. 1971). Because of wide availability
of different groups of antibiotics, which were cheaper and
easier in production, the trials of application of lysostaphin
were stopped for over two decades until the late 1990s.
During the last 15 years, there have been numerous reports
which definitely confirm the therapeutic potential of lysos-
taphin in the treatment of infections caused by staphylococci
including MRSA and VISA.
Climo et al. (1998) compared the effectiveness of various
regimens of intravenous dosing of lysostaphin to that of
vancomycin in the rabbit model of aortic valve endocarditis
caused by a clinical methicillin-resistant S. aureus isolate.
The reduced susceptibility to vancomycin of the strain was
generated through the stepwise passage in the presence of
increasing concentrations of glycopeptides. The most active
regimen, lysostaphin given three times daily, produced ster-
ile vegetations in 10 of 11 treated rabbits, while the number
of bacteria in the untreated controls increased to the level of
8.5×103CFU/g. In contrast, vancomycin given twice daily
sterilized no vegetations and reduced vegetation bacterial
counts by only 4.8×103CFU/g compared to the counts in
the untreated controls. The authors also revealed that the
enzyme was well tolerated by the rabbits, and no evidence
of immunological reactions following up to 9 weeks of
intravenous administration of the lysostaphin was observed.
The same researchers confirmed excellent bactericidal ac-
tivity of lysostaphin for the treatment of experimental aortic
valve endocarditis caused by a clinical isolate of VISA
(Patron et al. 1999), while in the case of experimental aortic
valve endocarditis caused by oxacillin-resistant S. epidermi-
dis, it was necessary to use a combination of lysostaphin and
nafcillin. The combination of these two agents was as ef-
fective as vancomycin alone and significantly better than
lysostaphin or nafcillin alone (Kiri et al. 2002).
The group of O’Callaghan at LSU Medical Center in
New Orleans revealed that lysostaphin is effective in treat-
ing keratitis caused by methicillin-sensitive or methicillin-
resistant S. aureus and endophthalmitis mediated by MRSA.
Methicillin-resistant S. aureus strain 301 (MRSA 301) or a
methicillin-sensitive strain of low virulence, ISP546, was
intrastromally injected into rabbit corneas. Rabbit eyes were
treated topically every 30 min from 4 to 9 or 10 to 15 h
postinfection with 0.28 % lysostaphin or 5 % vancomycin.
With early therapy (4–9 h postinfection), lysostaphin steril-
ized all MRSA 301-infected corneas, whereas untreated
corneas contained 6.52×103CFU/cornea. Corneas infected
with MRSA 301 and treated similarly with vancomycin
retained 2.3±0.85×103CFU/cornea, and none were sterile.
When therapy was begun later (10–15 h postinfection), the
residual bacteria in lysostaphin-treated eyes were signifi-
cantly less numerous than in vancomycin-treated eyes
(0.58±0.34 vs. 5.83±0.16×103CFU/cornea), respectively
(Dajcs et al. 2000). O’Callaghan and coworkers also tested
the possibilities of application of lysostaphin in the treat-
ment of experimental endophthalmitis mediated by
coagulase-negative Staphylococcus species, which in fact
is the leading cause of postsurgical endophthalmitis. As a
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result of some modifications of the amino acid composition
of interpeptide bridge in the peptidoglycan, the coagulase-
negative staphylococci are generally more resistant to lysos-
taphin. Interestingly, the results of the investigation were
successful. Treatment with lysostaphin significantly reduced
the bacterial count as compared with untreated eyes for 13
strains tested in vivo, and only in the case of two S. haemo-
lyticus strains, two methicillin-resistant S. epidermidis
(MRSE) strains, and one Staphylococcus cohnii strain, the
results of treatment were not satisfactory. Treatment with
lysostaphin reduced the colony forming units per milliliter
of the number of methicillin-sensitive S. epidermidis strains
by 6-logs; for Staphylococcus warneri, there was a 2-log
reduction; and for the other species, a 4-log reduction in
colony forming units per milliliter relative to untreated eyes
(McCormick et al. 2006).
An important problem in the antibiotic therapy of staph-
ylococcal infections is the ability of this group of micro-
organisms to form a biofilm. Some reports have shown that
lysostaphin is a promising agent also in the eradication of
biofilm of staphylococci from biotic and abiotic surfaces.
The investigation carried out by Wu et al. (2003) revealed
that lysostaphin not only killed S. aureus growing in bio-
films, but also disrupted the extracellular matrix of S. aureus
biofilms in vitro on plastic and glass surfaces at concentra-
tions as low as 1 μg/mL. In contrast, even high concentra-
tions of oxacillin (400 μg/mL), vancomycin (800 μg/mL),
and clindamycin (800 μg/mL) had no effect on the estab-
lished S. aureus biofilms in this system, even after 24 h.
Higher concentrations of lysostaphin also disrupted S. epi-
dermidis biofilms. The activity of lysostaphin towards bio-
films built by clinical and reference S. aureus and S.
epidermidis was also confirmed by Walencka et al. (2005).
The lysostaphin susceptibility of Staphylococcus tested
strains of planktonic and biofilm cultures varied and was
strain dependent. The authors noticed a synergistic effect of
the enzyme and some antibiotics: oxacillin, vancomycin,
and linezolid in the eradication of staphylococcal biofilm.
The combination of lysostaphin and linezolid was effective
in disruption of biofilm formed by MSSA, MRSA, and even
hVISA strains. The biofilm of the hVISA strain was resis-
tant to the combination of the enzyme with oxacillin and
vancomycin. The resistance towards the combination of
lysostaphin and oxacillin was also noticed in the case of
biofilm of 6756/99 MRSE strain (Walencka et al. 2005,
2006). Recently, Aguinaga et al. (2011) studied the syner-
gistic biofilm eradication effect of the combination of lysos-
taphin and a broader spectrum of antibiotics. Lysostaphin
combined with cefazolin, clarithromycin, doxycycline, lev-
ofloxacin, linezolid, and quinupristin/dalfopristin exhibited
a synergistic effect against the MSSA strain in terms of its
minimal biofilm eradication concentration (MBEC), with
reductions of 2–11-fold dilutions. The synergistic effect of
lysostaphin in combination with clarithromycin, doxycy-
cline, levofloxacin, rifampicin, and teicoplanin against the
MRSA strain, with 2–14-fold reduction of their MBEC, was
also confirmed (Aguinaga et al. 2011). The studies carried
out by Biosynexus Incorporated (Gaithersburg) revealed
that lysostaphin could also eradicate in vivo established S.
aureus biofilms on implanted jugular vein catheters in mice.
The enzyme administered at 15 mg/kg in combination with
50 mg/kg nafcillin three times daily for 4 days eradicated
established S. aureus, including MRSA, biofilms from
implanted catheters, and sterilized heart and liver infections
of S. aureus-infected mice. Furthermore, a single pre-
instillation of 10 mg/kg lysostaphin in catheters completely
protected catheterized mice from a subsequent biofilm in-
fection (Kokai-Kun et al. 2009). In 2003, the Biosynexus
Company presented results of another interesting investiga-
tion. That study demonstrated that a single application of
0.5 % lysostaphin (actual dose, approximately 150 μg of
lysostaphin), formulated in a petrolatum-based cream, dra-
matically reduces S. aureus nasal colonization in 100 % of
animals tested and eradicates S. aureus nasal colonization in
93 % of animals in a cotton rat model. A single dose of
lysostaphin cream was more effective than a single dose of
mupirocin ointment in eradicating S. aureus nasal coloniza-
tion in this animal model (Kokai-Kun et al. 2003). Similar
results were obtained by Cui et al. (2010), who used chitosan-
o/w cream incorporated with lysostaphin. The anterior nares
are considered as a primary ecological niche for S. aureus, and
the nasal colonization by this opportunistic pathogen increases
the risk of infection development. Clearance of S. aureus nasal
colonization could greatly reduce this risk.
During the last 2 years, a completely new approach of
application of lysostaphin in the clinical area has been
developed. The enzyme is immobilized or simply adhered
on the surface of medically important materials such as
meshes which are used in herniorrhaphy or wound dressing.
The results of preliminary research are very promising.
Miao et al. (2011) immobilized lysostaphin on the surface
of cellulose fibers, which were processed to obtain bandage.
The resulting material showed high activity against S. aure-
us in in vitro skin model with low toxicity toward keratino-
cytes. The aim of the study carried out by Belyansky et al.
(2011) was to determine whether lysostaphin adhered to
porcine mesh can impact host survival in the animal model.
Animals implanted with lysostaphin containing mesh had a
dramatically improved rate of survival. Only 1 out of 30 rats
with bacterial inoculum not treated with lysostaphin sur-
vived. By comparison, all of the 25 lysostaphin-treated
animals were completely cleared of S. aureus when chal-
lenged with bacterial concentrations of 1×106 and 1×108
with maintenance of mesh integrity for 60 days.
The next interesting proposal of the application of lysos-
taphin was that of Pangule et al. (2010). The researchers
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designated and obtained carbon nanotube–lysostaphin con-
jugates. These enzyme-based composites were highly effi-
cient in killing MRSA (>99 % within 2 h) without release of
the enzyme into the solution. Additionally, these films were
reusable and stable under dry storage conditions for a
month. The authors suggest that the enzyme-based film
formulations may be used to prevent growth of staphylo-
cocci on various common surfaces in hospital settings.
Staphylococci are also one of the most important pathogens
of wild and domestic animals. In recent years, an evident
increase in the number of reports in the isolation of MRSA
from pigs and calf has been observed. To address this issue,
some interesting propositions of the application of lysostaphin
in veterinary, especially for the treatment of bovine mastitis,
have been presented. Oldham andDaley infected the mammary
glands of 30 Holstein-Freisian dairy cattle with S. aureus in all
quarters. Next, the infected animals were injected through the
teat canal with a single dose of recombinant lysostaphin (dose
response 1 to 500 mg) or after three successive p.m. milkings
with 100 mg of recombinant lysostaphin in 60 mL of sterile
phosphate-buffered saline. Animals were considered cured if
the milk remained free of S. aureus for a total of 28 milkings
after the last treatment. The cure rate of quarters receiving
recombinant lysostaphin (100 mg in sterile phosphate-
buffered saline, administered over three consecutive p.m. milk-
ings) was 20 % compared with 29 % for sodium cephapirin in
saline and 57 % for a commercial antibiotic formulation, re-
spectively (Oldham and Daley 1991). These observations were
lately confirmed by the group of Jakubczak et al. (2010). High
in vitro bactericidal activity of lysostaphin against S. aureus
isolated from mastitis was recently confirmed by Zhang et al.
(2012). However, the most advanced proposition of the appli-
cation of lysostaphin for the protection of cattle against staph-
ylococcal mastitis was proposed by Wall and coworkers. In
2001, the researchers revealed possibilities of production of
biologically active lysostaphin in the mammary glands of mice.
The obtained lines of transgenic mice, in which the 5′-flanking
region of the ovine β-lactoglobulin gene directed the secretion
of lysostaphin into milk, exhibit substantial resistance to an
intramammary challenge of 104CFU of S. aureus, with the
highest expressing line being completely resistant (Kerr et al.
2001). Finally, in 2005,Wall’s group produced transgenic cows
secreting lysostaphin at concentrations ranging from 0.9 to
14 μg/mL of their milk. Protection against S. aureus mastitis
appears to be achievable with as little as 3μg/mL of lysostaphin
in milk. The milk’s ability to kill S. aureuswas confirmed by in
vitro assays (Wall et al. 2005).
The foodborne illnesses caused by S. aureus and other
Staphylococcus species are usually associated with products
that cannot be preserved by thermal methods, such as meat,
dairy, poultry, egg, and cream-filled bakery products. In this
case, the favorable way of pathogen inactivation is applica-
tion of bacteriocins. Because of the biological activity of
lysostaphin, this protein seems to be a very good candidate
for a natural food preservative. Unfortunately, very few
studies have addressed the preservation of food products
against Staphylococcus growth by this enzyme application.
The gene encoding lysostaphin has been cloned and
expressed into Lactobacillus casei, Lactobacillus curvatus,
and Lactobacillus sake (Gaier et al. 1992; Cavadini et al.
1996, 1998). The transgenic L. curvatus producing biolog-
ically active enzyme was successfully used for preservation
of fermented sausages. In this case, a 90 % reduction of
activity of the enzyme was observed, but the residual activ-
ity was sufficiently high to reduce Staphylococcus counts
from 104 to 105CFU/g within 2 to 3 days to below the level
of detection (Cavadini et al. 1998). Also, purified recombi-
nant lysostaphin expressed in E. coli cells has been devel-
oped for food protection against S. aureus by Szweda et al.
(2007). The population of S. aureus in milk preserved at 4 °C
by lysostaphin added up to concentrations of 1.5 or 3.0 μg/
mL was reduced by 0.73 and 0.92 log(CFU/mL) in compar-
ison to control samples without enzyme addition. The pro-
tective influence of lysostaphin was diminished in case of
milk storage at 20 °C prolonged up to 24 h. Furthermore, a
final reduction level by 0.92 log(CFU/mL) was achieved
after 24 h of pork storage. The smaller and more dependent
on enzyme concentration inactivation of S. aureus was ob-
served in the case of mayonnaise salads. The presented
results cannot be classified as really satisfactory; however,
in our opinion, the enzyme has a great potential as a food
preservative.
Recently, Desbois and Coote (2011) revealed a strong
bactericidal synergy of lysostaphin in combination with
some other antimicrobial peptides. It is also highly possible
that the bactericidal effect of the enzyme can be enhanced
by some food preservatives or natural substances (so far not
tested). Some of the combinations of lysostaphin and other
agents can be more effective in the eradication of staphylo-
cocci from food products. Additionally, resistance of other
bacteria against lysostaphin activity makes this enzyme
useful especially for the preservation of food containing
probiotic microflora. The crucial issue for large-scale appli-
cation of the enzyme is its availability and low costs of its
production. In fact, recently, several efficient heterologous
systems of expression of lysostaphin have been developed
(Mierau et al. 2005a, b; Szweda et al. 2005; Sharma et al.
2006). However, in our opinion, it is still necessary to make
an effort to do scaling up and improve performance of
proposed technologies.
LasA-staphylolysin
In fact, the only bacterial PH that has been tested as a potential
staphylolytic agent except lysostaphin is the enzyme LasA
also called staphylolysin produced by Pseudomonas
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aeruginosa (Kessler et al. 1993; Kessler and Ohman 2004).
LasA is synthesized as an inactive precursor that is composed
of a signal peptide (3 kDa), a propeptide (22 kDa), and a
mature catalytic domain (20 kDa) (Gustin et al. 1996; Schad
and Iglewski 1988). The signal peptide is cleaved as the
protein crosses the inner membrane, and the propeptide
remains covalently attached until the protein is secreted from
the cell, then it is hydrolyzed by other extracellular proteases
produced by P. aeruginosa (Kessler et al. 1998). LasA is
implicated in a range of processes related to Pseudomonas
virulence, including stimulation of ectodomain shedding of
the cell surface heparan sulfate proteoglycan syndecan-1 and
elastin degradation in connective tissue (Park et al. 2001;
Vessillier et al. 2001). Similar to lysostaphin, the enzyme
cleaves the pentaglycine bridges of the cell wall of peptido-
glycan of S. aureus. Moreover, LasA is “tolerant” for some
modifications of amino acid composition within pentaglycine
interpeptide bridge, and in consequence, the enzyme is able to
lyse also other types of staphylococci including
Staphylococcus saprophyticus, S. epidermidis, and S. warneri
(Brito et al. 1989; Vessillier et al. 2001; Kessler et al. 2004).
The detailed catalytic mechanism of this protein including
recognition a wider array of substrates has been solved by
Spencer et al. (2010) who determined the three-dimensional
structure of LasA.
In terms of the application of staphylolysin as a bacteri-
cidal agent against staphylococci in animal models, several
interesting reports have been presented by the group of
Barequet from Tel Aviv University (Israel). The authors
revealed that staphylolysin is effective in the treatment of
both MSSA and MRSA experimental keratitis. The enzyme
completely sterilized the infected rat corneas when treatment
was initiated 4 h after infection and reduced the number of
viable bacteria (colony forming units) in both MSSA and
MRSA-infected corneas by 3–4 orders of magnitude as
compared to controls when treatment was initiated 10 h
postinfection. Furthermore, staphylolysin was found to be
even more effective than vancomycin in eradicating MRSA
cells (Barequet et al. 2004). Satisfactory activity of LasA
was confirmed in the investigation carried out with rat
corneas infected with clinical isolates of MRSA strains.
The staphylolysin-treated eyes infected with the MRSA
strains were either completely sterilized or showed 3–4
orders of magnitude decrease in the number of CFU/cornea
in comparison to control. The histopathological analysis of
the methicillin-sensitive (MSSA) strain-infected eyes at 84 h
after completion of treatment showed moderate inflamma-
tion in the staphylolysin-treated eyes as compared with
extensive abscess formation in the control group (Barequet
et al. 2012). The same group demonstrated that staphyloly-
sin is effective in the treatment of experimental endophthal-
mitis in rats caused by MRSA strain. In eyes treated by the
single injection regimen, staphylolysin reduced the mean
CFU value per vitreous 3-fold as compared to control (2,055±
3,144 and 6,432±6,389 CFU/vitreous, respectively; P00.02).
The repeated injection protocol was more effective, reducing the
mean CFU value per vitreous by 2 orders of magnitude
as compared to control (1,148±3,096 and 143,519±
151,358 CFU/vitreous, respectively; P 00.0005).
Histopathological analysis showed no structural damage in the
eyes injected intravitreally with staphylolysin (Barequet et al.
2009).
Though the results presented above are promising, sur-
prisingly enough, there are no more information about
investigations concerning the application of staphylolysin
for the treatment of infections caused by S. aureus and other
staphylococci. In comparison to lysostaphin, the LasA rep-
resents a broader spectrum of activity and could be tested for
example for the treatment of infections caused by S. epider-
midis, an opportunistic pathogen of growing importance. It
is also interesting that there is no information about the
production of the enzyme using heterologous expression
system. In all presented reports, the protein was isolated
from P. aeruginosa culture supernatants. In our opinion,
new methods of production and application of LasA are an
interesting field for research in the nearest future. It can be
assumed that the results of these investigations would lead
to many applications of this enzyme.
Staphylococcal autolysins
As it was mentioned above, PHs are essential for many
important processes of modification of bacterial cell wall
envelope. In the living cells, they are expressed in a pre-
cisely defined amount and at an accurate time. This timing
protects bacteria against possible autolysis. On the other
hand, several reports revealed that the bacterial cells treated
produced by themselves PHs, but taken from the exogenous
sources, are killed as a result of hydrolysis of peptidoglycan
constituent of their cell wall.
Since the first report on S. aureus autolysins (Welsch and
Salmon 1950), a variety of intracellular and extracellular
enzymes hydrolyzing peptidoglycan have been reported
and characterized in this bacterium (Sugai 1997). In our
opinion, some of them deserve a special attention from the
point of view of their application as bactericidal enzymes
against staphylococci. According to our best knowledge, so
far, studies on this subject have not been performed. This is
surprising, especially taking into account the number of
investigations of potential applications of lysostaphin or
even LasA.
One of the most interesting staphylococcal autolysins is
the ALE-1 enzyme produced by Staphylococcus capitis
EPK1. Its primary structure is very similar to lysostaphin,
and the identity of the putative functional domains of the
enzymes is 83 % at the amino acid level. Both are
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glycylglycine endopeptidases and hydrolyse the pentaglycine
interpeptide bridges of S. aureus peptidoglycan. They consist
of a multiple repeat N-terminal domain fused to an active site
containing a C-terminal substrate (peptidoglycan)-specific do-
main. The ALE-1 enzyme has been cloned and expressed inE.
coli cells, and its staphylolytic activity was confirmed with
heat-killed and viable S. aureus FDA209P (Sugai et al. 1997).
Another interesting glycylglycine endopeptidase autolysin
produced by S. aureus is the enzyme called LytM. Taking into
account the putative functional domains, it shows 51 and 50%
identity with lysostaphin and ALE-1, respectively. All these
enzymes are members of the Zn2+ protease family and contain
a homologous 38-amino-acid-long motif, Tyr-X-His-X11-Val-
X12/20-Gly-X5-6-His. However, in contrary to the two proteins
described earlier, the gene encoding LytM is located on the
chromosome, not on the plasmid. It may indicate that LytM
plays an important role in actively growing and dividing cells.
The enzyme was first described in 1997 (Ramadurai and
Jayaswal 1997), and in 1999, it was overexpressed in E. coli
as a fusion protein with a six-histidine residue tag at its N-
terminus (Ramadurai et al. 1999). The recombinant protein
effectively hydrolyzed peptidoglycan of heat-killed and auto-
claved S. aureus N450 and was completely inactive towards
the cell wall of Micrococcus luteus, which does not contain a
pentaglycine motif in its cell wall. The protein has been
crystallized and its active site domains have been mapped
(Firczuk et al. 2005; Odintsov et al. 2004). Despite the evident
similarity of amino acid sequence, the enzymes are differently
affected by various physical and chemical factors. For exam-
ple, lysostaphin and LytM are strongly inhibited in the pres-
ence of Fe2+ ions, while the activity of ALE-1 is even higher
in the presence of these ions. Surprisingly, NaCl and KCl
appeared to inhibit the activity of LytM at concentrations as
low as 100 mM. The optimum pH values for enzyme activity
are in the ranges of 6–9, 7–9, and 5–8 for lysostaphin, ALE-1,
and LytM, respectively. The LytM exhibits unexpected ther-
mostability, which is not observed in the case of the two other
enzymes. The activity of LytM is stable for 15 min at 100 °C
and is destroyed on heating for 30 min (Schindler and
Schuhardt 1964; Sugai et al. 1997; Ramadurai et al. 1999).
These details can be crucial due to its practical applications;
for example, Sabala and coworkers using a newly developed
model of chronic S. aureus-infected eczema observed evident
lower activity of LytM in comparison to lysostaphin (Sabala et
al. 2012).
The major autolysin of S. aureus is the AtlA protein
(Oshida et al. 1995) that is quite similar in both sequence
and domain organization to the AtlE, the predominant PH of
S. epidermidis (Heilmann et al. 1997). Both of them are
bifunctional, composed of an amidase domain and a gluco-
saminidase domain, which are separated by three repetitive
sequences. The atl gene products undergo proteolytic pro-
cessing, and as a result, two extracellular lytic enzymes can
be found in the culture broth of both staphylococci. The
amidase domain of AtlE was expressed in E. coli cells as a
N-terminal His-tagged fusion protein and the product of
expression exhibited staphylolytic activity. The analysis of
the products of hydrolysis of S. aureus peptidoglycan
revealed that the enzyme can be classified as a N-acetylmur-
amyl-L-alanine amidase (Biswas et al. 2006). These results
clearly indicate that also the most important staphylococcal
autolysins, derived from exogenous sources, could be used
as staphylolytic agents. The same results can be expected in
the case of other staphylococcal PHs.
Bacteriophage lysins
The double-stranded DNA bacteriophages are released from
bacterial cell host using a holins–endolysin system
(Borysowski et al. 2006). Lysins are the enzymes targeting
the integrity of the cell wall of the host and are designed to
hydrolyze one of the four major bonds present in the pepti-
doglycan. Usually they do not have any signal sequences
and are dependent on a second protein, called holins, to
reach their substrate (Wang et al. 2000). The holins form
pores in the inner membrane of the infected cells resulting in
access of lysin to the peptidoglycan causing rapid cell lysis
(Young and Blasi 1995). For phages, both the holins and the
lysins are essential for host cell destruction. There are also
some bacteripohages producing endolysins provided with a
signal peptide. These enzymes are released from the cells of
infected bacteria through the general secretion system (Park
et al. 2007). However, when lysins of both groups are used
as recombinant enzymes and applied exogenously, they
rapidly lyse Gram-positive cells upon direct contact with
peptidoglycan. The Gram-negative bacteria are more resis-
tant to lysin activity because of the presence of an outer
membrane (Loessner 2005; Fenton et al. 2010a). However,
removing the outer membrane with specific compounds
such as chloroform, EDTA, or detergents results in full
sensitivity of these bacteria to the activity of lysins.
During the last decade, several interesting endolysins
with bactericidal activity against staphylococci have been
identified, isolated, and characterized. Some of them were
tested as potential therapeutic agents or food preservatives.
In general, S. aureus phage lysins display a multi-domain
modular structure comprising of a C-terminal cell wall bind-
ing domain and two N-terminal catalytic domains.
Examples include LysK, MV-L, phi11, and LysH5
(O’Flaherty et al. 2005; Donovan et al. 2006; Rashel et al.
2007; Obeso et al. 2008). One of the most promising seems
to be the 495 aa endolysin LysK derived from staphylococ-
cal phage K. O’Flaherty and coworkers cloned and
expressed LysK in Lactococcus lactis. The obtained lacto-
coccal lysates containing recombinant LysK were found to
inhibit a range of different species of staphylococci isolated
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from bovine and human infection sources, including MRSA
(O’Flaherty et al. 2005). The group of Becker et al. (2008)
effectively expressed the C- and N-terminal His-tag version
of the enzyme in E. coli cells. The authors found some
problems with purification of N-His-LysK, which was co-
purified with multiple smaller proteins, probably the prod-
ucts of degradation of the target protein, that were absent
while full-length C-His-LysK was purified. The produced
endolysin was found to exhibit highly bactericidal activity
against S. aureus strain MRSA USA300. LysK construct
with the C-His-LysK yielding a MIC of 32.85 μg/mL and
N-His-LysK with a MIC of 80 μg/mL, in comparison with
lysostaphin, inhibits the growth of the same strain at a
concentration of 0.096 μg/mL. The enzyme maintained its
activity at either 4 or −80 °C for up to 60 days. It was also
revealed that lysostaphin and LysK (C-terminal His-tag
version) act synergistically to kill MRSA. In the assay
carried out by the group of Becker, two of the most effective
conditions were at concentrations of 0.027 and 5.71 μg/mL
and 0.018 and 11.43 μg/mL for lysostaphin and LysK,
respectively, representing concentrations that correspond to
30 and 18 % and 16 and 33 % of each compound MIC,
respectively (Becker et al. 2008). Detailed characteristic of
the enzyme in terms of factors influencing its kinetic fea-
tures has been presented by the group of Filatova et al.
(2010). The authors also proposed the methods of stabiliza-
tion of the enzyme. LysK incubated at 22 °C for 1 month
loses over 90 % of its activity. The stability of the enzyme in
the higher temperatures can be dramatically enhanced by the
addition of low molecular weight polyoles (glycerol, sorbi-
tol, sucrose, or trehalose) to the concentration over 50 % and
Ca2+ ions to the concentration in the range of 1–5 mM
(Filatova et al. 2010).
The LysK contains two enzymatic domains, one of which
is an N-acetylmuramoyl-L-alanine amidase and the other a
cysteine/histidine-dependent amidohydrolase/peptidase des-
ignated CHAPk. In 2009, two groups, Becker et al. (2009)
and Horgan et al. (2009), published the results of their inves-
tigations aiming at the analysis of bactericidal activity of
separated domains of LysK. The group of Becker revealed
that the truncated version of LysK, containing just the CHAP
domain, lyses S. aureus cells in zymogram analysis, plate
lysis, and turbidity reduction assays but has no detectable
activity in the MIC assay. In contrast, truncations harboring
just the amidase lytic domain show faint activity in both the
zymogram and turbidity reduction assays, but no detectable
activity in either plate lysis orMIC assays. Themost important
observation of this investigation was that the fusion of the
CHAP domain to the SH3b domain has near full-length LysK
lytic activity, suggesting the need for a C-terminal binding
domain. Both LysK and the CHAP-SH3b fusion were shown
to lyse untreated S. aureus and the coagulase-negative strains
(Becker et al. 2009). Interestingly, Horgan et al. (2009)
revealed that separated CHAP domain (consisted of amino
acids 1–156 of full-length LysK) was approximately 2-fold
more active against live staphylococcal cells than the native
enzyme. Additionally, the truncated enzymewas conveniently
overexpressed in a highly soluble form (Horgan et al. 2009).
Using the in vivo imaging system, it was also demonstrated
that CHAPk effectively eliminates S. aureus from the nares of
artificially infected BALB/c mice (Fenton et al. 2010b). The
lytic spectrum of the recombinant, effectively expressed in E.
coli CHAPk (10 mg from 1 L of bacterial culture), includes all
staphylococcal species and also members of the genera
Micrococcus, Streptococcus, Nesterenkonia, Arthrobacter,
Leuconostoc, and Carnobacterium. The enzyme was active
from pH 6 to 11, with an optimum activity at pH 9 and
temperature varied from 5 to 40 °C, with an optimum activity
at 15 °C, which can be a crucial in some applications (Fenton
et al. 2011). The Hyglos GmbH (Regensburg, Germany) con-
structed a chimeric lysin containing an enzymatic active do-
main—cysteine and histidine-dependent aminopeptidase/
hydrolase (CHAP) from LysK and cell wall binding domain
from lysostaphin. The excellent activity of the chimeric en-
zyme, called PRF-119, was confirmed on large groups of
MSSA (n0398) and MRSA (n0776) isolates. The MIC val-
ues were in the ranges 0.024–0.78 and 0.024–1.563 μg/mL,
respectively (Idelevich et al. 2011).
Recently, the group of Jun et al. (2011) isolated endolysin
SAL-1 the amino acid sequence of which differs from that
of LysK at only three residues: isoleucine instead of valine
at the 26th residue, glutamine instead of glutamic acid at the
114th residue, and histidine instead of glutamine at the
486th residue. In spite of the high degree of amino acid
sequence similarity, the newly discovered phage endolysin
SAL-1 has an approximately 2-fold lower MIC against
several S. aureus strains and higher bacterial cell wall-
hydrolyzing activity than LysK. The authors constructed
several mutants of SAL-1 and revealed that the amino acid
residue change contributing the most to this enhanced en-
zymatic activity is a change from glutamic acid to glutamine
at the 114th residue. It would be interesting to check the
activity of truncated enzyme containing only the CHAPk
domain with modified amino acid residue at position 114.
The enzyme has been effectively expressed in E. coli cells as
C-terminal His-tagged protein and should be also consid-
ered as a potential antistaphylococcal agent.
Another interesting antistaphylococcal lysine assigned
MV-L has been isolated from the phage øMR11. The en-
zyme consists of 481 amino acid residues and, similar to
other lysins, is composed of three functional domains:
exhibiting endopeptidase activity (amino acid residues 15
to 120), amidase (amino acid residues 199 to 322), and cell
wall recognition domain (amino acid residues 323 to 481).
The lysin rapidly and completely lysed cells of a number of
S. aureus strains tested, including methicillin-resistant S.
1166 Appl Microbiol Biotechnol (2012) 96:1157–1174
aureus (MRSA) and vancomycin-resistant S. aureus and a
subset of vancomycin-intermediate S. aureus (VISA) in
growing conditions. MV-L-mediated killing is specific to
S. aureus and not to other species, except for S. simulans.
MV-L exerted its staphylocidal effect synergistically with
glycopeptide antibiotics against VISA. The lysin efficiently
eliminated MRSA that had been artificially inoculated into
the nares of mice. The intraperitoneal administration of MV-
L also protected mice against MRSA septic death, without
any harmful effects (Rashel et al. 2007).
The in vivo antistaphylococcal activity has been also
confirmed in the case of lysin ClyS constructed by Daniel
et al. (2010). The chimeric lysin was obtained by fusing the
N-terminal endopeptidase domain of the S. aureus Twort
phage lysin with the C-terminal cell wall-targeting domain
from another S. aureus phage lysin (phiNM3), which dis-
played Staphylococcus-specific binding. The non-His-
tagged ClyS obtained in the expression host, E. coli, lysed
VISA, MSSA as well as MRSA strains of S. aureus in vitro.
ClyS was also active against other staphylococci: S. epider-
midis, including the biofilm-forming strain RP62A, S. sim-
ulans, and S. sciuri subsp. sciuri, did not exhibit activity
against other Gram-positive and Gram-negative bacteria,
including representatives of group A, B, C, and E strepto-
cocci, the oral streptococcal species S. gordonii and S.
salivarius as well as Streptococcus uberis, Bacillus cereus,
P. aeruginosa, and E. coli. But the most interesting and
promising results were obtained in mouse nasal decoloniza-
tion model. The 2-log reduction in the viability of MRSA
cells was seen in 1 h following a single treatment with ClyS.
Single intraperitoneal dose of ClyS also protected against
death caused by MRSA in a mouse septicemia model. ClyS
showed a typical pattern of synergistic interactions with
both vancomycin and oxacillin in vitro. More importantly,
ClyS and oxacillin at doses that were not protective individ-
ually, in combination, protected synergistically against
MRSA septic death in a mouse model (Daniel et al. 2010).
In a mouse model of skin colonization/infection with S.
aureus, the ClyS was shown to be more effective than
mupirocin. The lysin eradicated a significantly greater num-
ber of methicillin-susceptible S. aureus and methicillin-
resistant S. aureus bacteria; the 3- and 2-log reductions were
observed for ClyS and mupirocin, respectively, and no in-
fluence of produced antibodies against the lysine activity
was observed (Pastagia et al. 2011). In vitro and in vivo
activity was also confirmed for staphylococcal peptidogly-
can hydrolase LysGH15, which was first isolated from bac-
teriophage GH15. In animal experiments, a single
intraperitoneal injection of LysGH15 (50 μg) administered
1 h after MRSA injections at double the minimum lethal
dose was sufficient to protect mice (P<0.01). Bacteremia in
unprotected mice reached colony counts of about 107CFU/
mL within 3.5 h after challenge, whereas the mean colony
count in lysin-protected mice was less than 104CFU/mL or
even became undetectable (Gu et al. 2011a). It was also
found that the enzyme alleviates inflammation induced by
infection with lethal MRSA (Gu et al. 2011b).
High lytic potential towards S. aureus was also noticed in
the case of bacteriophage P-27/HP from sewage water. The
isolated endolysin produced by this phage assigned with the
same numerical code exhibited maximum in vitro lytic
activity at temperatures between 35 and 40 °C and pH 7.0.
In vivo experiments revealed considerable (99.9 %) elimi-
nation of S. aureus 27/HP from spleens of endolysin-treated
mice and had saved them from death due to infection (Gupta
and Prasad 2011a, b).
In the case of many interesting lysins, such as protein 17
of the bacteriophage P68, a bactericidal activity towards S.
aureus has been confirmed only using the in vitro tests. The
enzyme was tested on 35 clinical isolates of S. aureus, 50 %
of which were oxacillin-resistant. The purified lysin showed
a broader antimicrobial spectrum, compared to the host range
of phage P68. The phage lysed only 11 of all clinical strains,
whereas protein 17 displayed activity against 26 strains. This
suggested that the bacterial receptor required for phage at-
tachment differs from the ligand required for protein 17
binding (Takac and Blasi 2005). High thermostability was
noticed in the case of HydH5 lysin, produced by S. aureus
bacteriophage vB_SauS-phiIPLA88 (phiIPLA88). The en-
zyme retained 72 % of its activity after 5 min at 100 °C
(Rodríguez et al. 2011).
Several investigations confirmed potential usefulness of
some bacteriophage lysins as food preservatives. The purified,
recombinant LysH5 lysin, from bacteriophage øH5 was able
to kill rapidly S. aureus growing in pasteurized milk and the
pathogen was not detected after 4 h of incubation at 37 °C
(Obeso et al. 2008). Additionally, the results of the investiga-
tion carried out by García et al. (2009) suggest that activity of
lysin produced by øH5 can be enhanced by its combination
with other peptidoglycan hydrolases. A mixture of phages
øH5 and øA72 was more effective than each single phage.
The mixture of phages effectively inhibited S. aureus in UHT
and pasteurized whole fat milk. However, the phages produc-
ing lysins were less active in semi-skimmed raw milk, and
little inhibition was achieved in whole, raw milk. Killing of S.
aureus was observed at room temperature and at 37 °C, but
not at refrigeration temperature (García et al. 2009). The same
authors tested LysH5, the endolysin encoded by the staphylo-
coccal bacteriophage phi-SauS-IPLA88. When LysH5 was
combined with nisin, a strong synergistic effect was observed.
The MIC of nisin and LysH5 were reduced 64- and 16-fold,
respectively, as determined in checkerboardmicrotiter tests. In
addition, nisin enhanced 8-fold the lytic activity of LysH5 on
cell suspensions. Importantly, the synergy observed in vitro
was confirmed in challenge assays in pasteurized milk con-
taminated with S. aureus Sa9. Clearance of the pathogen was
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achieved only by the combined activity of both antimicrobials
(García et al. 2010). Recently, Rodriguez-Rubio and cow-
orkers constructed a strain of L. lactis producing recombinant,
biologically active LysH5. Despite the fact that almost 80% of
protein is retained in the cell and only about 20 % is secreted,
the strain seems to be a promising microorganism inhibiting
the growth of S. aureus in fermented food products
(Rodriguez-Rubio et al. 2012). Donovan et al. (2006) demon-
strated that the endolysin ø11 exhibits bactericidal activity at
the physiological pH and calcium concentrations found in
milk towards not only S. aureus, but also several species of
mastitis-causing CoNS, which makes it not only a potential
milk food product preservative, but also a promising anti-
mastitis agent. Additionally, Sass and Bierbaum (2007)
revealed that ø11 endolysin is able to hydrolyze staphylococ-
cal biofilm. It is important to remember that nature is still a
reservoir of probably a great number of staphylococcal bacter-
iophages which are not yet recognized. Recently, Kwiatek et
al. (2012) isolated and characterized of a novel virulent bac-
teriophage (MSA6) from a cow with mastitis. Isolated phage
was capable of infecting a wide spectrum of staphylococcal
strains of both human and bovine origin; however, the se-
quence of the lysin is still not known.
The number of publications concerning isolation, charac-
terization, and possibilities of the application of bacteriophage
lysins as antistaphylococcal agents rapidly increased during
the last 5 years. The presented results are very promising.
Much effort is required in elaboration of big scale technolo-
gies of their production and testing of their toxicity, allerge-
nicity, and eventually influence on the components of natural
flora of the human and animal body. However, it can be
assumed with high probability that in the near future, this
group of proteins will be used as food preservatives and in
the therapy of infections caused by staphylococci.
Conclusions
S. aureus is a major human and animal pathogen responsible
for a number of serious and sometimes fatal infections. The
emergence of antibiotic-resistant S. aureus strains has
resulted in significant treatment difficulties. Therefore, there
is an urgent need to develop novel antibacterial agents to
control this pathogen. One of the most promising solutions
of the problem could be the application of enzymes hydro-
lyzing cell wall peptidoglycan of S. aureus. The most im-
portant advantages of these enzymes are (1) high specificity;
in fact, most of the PHs described above are completely
inactive toward other than S. aureus groups of bacteria. As a
result, they are considered as safe for natural microbiota of
the infected organism; moreover, they can be applied for the
protection of fermented food products. On the other hand,
some of the PHs described above are characterized by
broader spectrum including coagulase-negative staphylo-
cocci—pathogens of growing importance and even bacteria
of other origin. As a consequence, it is possible to select the
most appropriate enzyme of particular therapeutic or tech-
nological problem which has to be solved. (2) Most inves-
tigations, carried out up to date, classified these substances
as safe, with low toxicity and immunogenicity; (3) most of
them have been successfully produced using heterologous
E. coli expression systems characterized with high efficien-
cy; (4) some of them act synergistically with other antimi-
crobial agents including antibiotics; (5) some of the PHs
described, especially of bacteriophage origin, are composed
of two catalytic domains, which recognize and hydrolyze
two different bonds within the peptidoglycan. It evidently
reduces the possibility of the creation of resistant strains; (6)
they are active even against multidrug-resistant strains and
can be used for eradication of bacteria growing in biofilm.
The summary characteristic of most promising antistaphy-
lococcal PHs is presented in Table 1.
Obviously, it is necessary to remember about several
limitations which have to be solved before using PHs as
therapeutic agents or food preservatives. The most impor-
tant issues, which at the current state of knowledge preclude
clinical or industrial application of these enzymes, have
been discussed below. It should be noted that in this respect
only lysostaphin has been tested at a sufficient level; how-
ever, it can be expected that trials of practical application of
other PHs will result in the same problems and limitations
which have been observed for lysostaphin. We have not
only presented the most important limitations but also dis-
cussed the methods of overcoming them.
1. However, at the current state of knowledge, the PHs,
including lysostaphin, are generally recognized as safe,
and it is necessary to intensify the studies on toxicity
and immunogenicity coming from using these enzymes.
The results of few confirmed production of anti-
lysostaphin antibodies occur in many different animal
models; however, their production did not significantly
affect the activity of the enzyme. Using a rabbit model
of ocular MRSA infection, Dajcs et al. (2002) achieved
very good effects of eradication of bacteria from both
immunized and non-immune rabbits. Additionally, no
adverse reactions were observed due to administration
of lysostaphin to immunized rabbits. No allergic reac-
tions nor other deleterious symptoms in the host animal
were obtained in the effect of intramammary infusion of
2–3 g (18–21 infusions) of recombinant lysostaphin
used as a S. aureus bovine mastitis agent (Daley and
Oldham 1992). However, the results of preliminary
research are promising, and there is no doubt that addi-
tional analyses according to regulatory requirements are
necessary.
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2. All of these enzymes except for lysostaphin are not
available commercially. The possibilities of production
of most PHs characterized above using efficient heter-
ologous E. coli expression systems have been described.
However, they are produced only in a small scale for
research needs. To date, only the industrial scale pro-
duction technology of lysostaphin has been developed.
Using a L. lactis nisin-controlled system, Mierau et al.
(2005a) optimized conditions of enzyme production at
the 3,000-L scale and obtained a final yield of lysosta-
phin after purification about 120 g per batch. The same
authors (Mierau et al. 2005b) revealed also that in the
small scale (1 L fermentor), the efficiency of the expres-
sion system can be increased to the level of 300 mg/L. It
is necessary to develop large-scale production technol-
ogies of other promising PHs, which require much
effort in each case. First of all, it would be necessary
to use other than E. coli expression systems for their
production. The most popular, commercially available
E. coli systems of recombinant protein production such
as pET or pBAD are usually useless for industrial scale
protein production. Low level of expression, instability
of strains producing proteins, incorrect folding of pro-
teins (e.g., creation of incorrect disulfide bonds and
production of the protein in the form of inclusion bod-
ies), strong dependence of level of production, and
conditions of fermentation are the most commonly ob-
served limitations. Large-scale production technologies
of many proteins have been developed using yeast ex-
pression systems, especially Picha pastoris and
Sachcaromyces cerevisiae. Surprisingly to date, there
are no information about trials of heterologous produc-
tion of any PHs in yeast cells. There is no doubt that
intense research on this subject should be done as there
is a high possibility of selection expression host for PH
production better than E. coli. Enhanced availability of
the proteins will reduce their prices, which can be cru-
cial not only for its application in medicine, veterinary,
and food technology, but also for further tests of their
properties during preclinical and clinical research. At
the moment, the price of 1 and 15 mg of lysostaphin
produced by a leading supplier is 100 and 800 €, re-
spectively, which can be a problem even for its appli-
cation as a therapeutic agent and is completely
unacceptable for its use as a food preservative.
3. Another challenge is to develop the technologies of
formulation which could guarantee a long-term stability
of the enzymes without loss of their activity.
4. The effectiveness of eradication of the bacteria from the
infected tissue will also depend on the method of protein
administration. The importance of both issues—formu-
lation and administration—has been partially investigat-
ed by the group of Walsh et al. (2003). The authors
improved the pharmacokinetics of lysostaphin by its
PEGylation with branched 40 kDa PEG. According to
in vitro tests, the PEGylated enzyme is characterized by
lower activity in comparison to the unconjugated en-
zyme. The compensate of the partial decrease of activity
of PEGylated enzyme was an evident increase of its
half-life in mice blood serum. PEGylated lysostaphin
injected intravenously had a drug half-life in serum of
up to 24 h and resulted in much higher plasma drug
concentrations than an equal dose of unconjugated
lysostaphin, which had a half-life of less than 1 h.
Additionally, the PEGylation resulted in a greater than
10-fold reduction in antibody affinity in comparison to
unconjugated protein. These results significantly en-
hance the therapeutic value of lysostaphin and other
PHs as intravenous antistaphylococcal agent.
5. The natural consequence of treatment of bacteria with
bactericidal or bacteriostatic agent is selection of
mutants resistant to their activity. The problem is espe-
cially common when the therapy is carried out for a long
period of time and only with using one agent. Selection
of S. aureus mutants with reduced susceptibility to
lysostaphin has been observed by several authors. The
selected mutants are characterized with mutations with-
in fem or lyrA operon which resulted in modification of
amino acid composition of interpeptide bridges-the mo-
lecular target of lysostaphin and also several other PHs
described in this review (de Jonge et al. 1993; Boyle-
Vavra et al. 2001; Grundling et al. 2006). In fact, this
limitation can be surmounted by using therapies that
contain multiple antimicrobial agents. To date, several
successful trials of lysostaphin containing combination
treatments have been described. The enzyme shown to
be synergistically bactericidal in combination with var-
ious agents, including antibiotics (Polak et al. 1993;
Climo et al. 1998; Kiri et al. 2002; Walencka et al.
2006), antimicrobial peptides (Desbois and Coote
2011), and even some natural products, e.g., tea tree
oil (LaPlante 2007). The similar effects have been ob-
served in the case of several other PHs, e.g., ClyS,
which showed synergistic interactions with vancomycin
and oxacillin. It may be assumed with a high probability
that future research will lead to the discovery of prom-
ising combinations of PHs with other antimicrobial
compounds. The benefit of the combinations of various
antimicrobial agents is not only limited to the develop-
ment of resistance phenomenon but also usage of lower
doses of agents essential for successful therapy.
PHs seem to be promising antistaphylococcal agents,
which is confirmed by a number of investigations whose
results we have presented in this review. The discussions
presented above clearly indicate that it is possible to solve
1170 Appl Microbiol Biotechnol (2012) 96:1157–1174
most of the problems which currently preclude application
of these enzymes as therapeutic agents in human and animal
infections or as a food preservative. However, still much
effort on this subject is required. The main goals of the
authors of this review were to highlight the therapeutic and
prophylactic potential of antistaphylococcal PHs and indi-
cate the most crucial limitations of their practical application
at the current state of knowledge as well as encourage
readers to take any form of effort which could result in
practical usage of these enzymes in medicine, veterinary,
and the food industry in the nearest future.
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